KALY - Kali-Extracts Announces 25 mg CBD Extract Formulation For $600 Million Cannabis Beverage Market
March 29 2019 - 10:00AM
InvestorsHub NewsWire
KALY - Kali-Extracts Announces 25
mg CBD Extract Formulation For $600 Million Cannabis Beverage
Market
Dallas, TX -- March 29, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today announced finalizing it’s all new 25 mg
CBD Extract formulation for beverage infusion. KALY’s
patented extraction process already produces a 10 mg CBD
formulation for Puration, Inc.’s (USOTC:
PURA) (“PURA”) leading EVERx CBD Sports Water. Few CBD
beverages today even have 5 mg of CBD and now KALY will supply a 25
mg formulation. Management thoroughly evaluated the 25 mg CBD
formulation for infusion into a drink that is clear looking and
tasting in a suspension with an effective retail shelf-life.
KALY indicates its formulation will be on shelves infused
into its first beverage within the next 30 days.
KALY earlier this week announced
that the State of Texas plans to remove hemp as a controlled
substance next week in conjunction with the United States 2018
Farm Act is just the type of market condition management is looking
for to support the implantation of the previously announced
cannabis extraction lab to be dedicated to the 100 acre hemp farm
to be operated by partner Nouveau (USOTC:
NOUV). KALY and NOUV plan to partner on the development
of a proprietary hemp cultivar dedicated to the advancement of
KALY’s pharmaceutical extract developments. The continuing
liberalization of cannabis laws such as the hemp removal as a
controlled substance in Texas, supports the work KALY is
advancing.
Last week, KALY published a
research report on the recent pilot
treatment of Chronic Obstructive Pulmonary Disease (COPD) in
primates using an extract derived from KALY’s patented cannabis
extraction process. The report details the study method and
the significance of the study. The report includes specific
findings and due to the substantial findings, the report includes
guidelines for next stage tests.
The full report can be read on the
company’s website at www.kali-extracts.com.
Goldman Small Cap Research Report
has published an analyst research report on KALY that highlights
KALY’s cannabis pharmaceutical value. The report is available
under “research” on the OTCMarkets website. The research
report is the first report from Goldman Small Cap Research as part
of an ongoing research engagement. The report outlines the
company’s current positioning and potential, upcoming milestones.
The report is intended to augment the current information available
on the OTCMarkets website. The report is also available to read or
download, along with associated disclosures and disclaimers,
at www.GoldmanResearch.com.
KALY
is a health and wellness company set to generate revenue from its
patented cannabis extraction technology through overlapping
go-to-market strategies. In addition developing
pharmaceutical products internally and through partnerships, KALY
is utilizing is patented cannabis extraction process to develop
numerous wellness products both internally and through
partnerships. The first revenue generating contracts signed in
December of 2018 will be reflected in the company’s upcoming annual
report.
To learn more about the company
visit https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Apr 2023 to Apr 2024